Log in to search using one of your social media accounts:

 

FDA Clears Smart Watch to Detect Seizures, Manage Epilepsy FDA Clears Smart Watch to Detect Seizures, Manage Epilepsy

The FDA has cleared the first smart watch for seizure tracking and epilepsy management. The device uses advanced machine learning to identify convulsive seizures and send an alert via text and phone message to caregivers.FDA Approvals
Source: Medscape Medical News Headlines - Category: Consumer Health News Tags: Neurology & Neurosurgery News Alert Source Type: news

Related Links:

Source: Seizure: European Journal of Epilepsy - Category: Neurology Authors: Source Type: research
Discussion: Residue G1306 Neonatal laryngospasm and unusual distribution of myotonia, muscle hypertrophy, and weakness encourage direct search for the G1306E mutation, a hotspot for de-novo mutations. Successful therapy with the sodium channel blocker flecainide is due to stabilization of the inactivated state and special effectiveness for enlarged window currents. Our G1306E collection is the first genetically clarified case series from newborn period to adulthood and therefore helpful for counselling. PMID: 29774303 [PubMed - in process]
Source: Acta Myologica - Category: Neurology Tags: Acta Myol Source Type: research
Conclusions: In this review we will provide animal and human research data on the current clinical neurological uses for CBD individually and in combination with Δ9-THC. We will emphasize the neuroprotective, antiinflammatory, and immunomodulatory benefits of phytocannabinoids and their applications in various clinical syndromes. PMID: 29770251 [PubMed]
Source: Surgical Neurology International - Category: Neurosurgery Tags: Surg Neurol Int Source Type: research
Authors: Wang B, Gupta G, Singh M, Veerabhadrappa KVS, Mishra A, Chinnaboina GK Abstract The present study was designed to explore the effect of chronic administration of a new flavone [morusflavone, 5,7,4'-trihydroxy-8-(γ,γ-dimethylallyl)-2',3'-(10'-hydroxy-9',10'-dimethyl-cyclohex-8-enyl)-flavone (compound 1)] at doses of 25, 50, and 100 mg/kg, orally (p.o.) to pentylenetetrazole-induced kindling in rats (a model of human epilepsy). Compound 1 and four other compounds were isolated from the stem bark of Morus alba. The structure of compound 1 was elucidated and established using standard spectroscopic...
Source: Journal of Environmental Pathology, Toxicology and Oncology - Category: Environmental Health Tags: J Environ Pathol Toxicol Oncol Source Type: research
Source: Seizure: European Journal of Epilepsy - Category: Neurology Authors: Source Type: research
Source: Seizure: European Journal of Epilepsy - Category: Neurology Authors: Tags: Review Source Type: research
Publication date: Available online 18 May 2018 Source:American Journal of Kidney Diseases Author(s): Victoria Títoff, Heather N. Moury, Igor B. Títoff, Kevin M. Kelly There are 2 major categories of patients with seizures and chronic kidney disease (CKD): patients who develop acute symptomatic seizures in the setting of CKD and patients with epilepsy who at some point develop CKD. The incidence of uremic seizures with kidney failure is ∼10%. These seizures are often nonconvulsive and may mimic uremic encephalopathy. Recognition and management of such situations may be challenging for treating physicians ...
Source: American Journal of Kidney Diseases - Category: Urology & Nephrology Source Type: research
TRENTON, N.J. (AP) — U.S. regulators Thursday approved the first drug designed to prevent chronic migraines. The Food and Drug Administration’s action clears the monthly shot Aimovig for sale. It’s the first in a new class of long-acting drugs for preventing migraines. Three other shots are expected to win approval by next year, and several pills for preventing migraines are being tested. Current prevention treatments include pills originally developed for epilepsy and other conditions, and the wrinkle reducer Botox, but many patients abandon them because they don’t provide enough relief or cause se...
Source: WBZ-TV - Breaking News, Weather and Sports for Boston, Worcester and New Hampshire - Category: Consumer Health News Authors: Tags: Health News Local TV Migraines talkers Source Type: news
Conditions:   Epilepsy;   Seizures;   Drug Resistant Epilepsy Intervention:   Device: Vagus Nerve Stimulation (VNS) Therapy Sponsor:   LivaNova Recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
(TRENTON, N.J.) — U.S. regulators Thursday approved the first drug designed to prevent chronic migraines. The Food and Drug Administration’s action clears the monthly shot Aimovig (AIM’-oh-vig) for sale. It’s the first in a new class of long-acting drugs for preventing migraines. Three other shots are expected to win approval by next year, and several pills for preventing migraines are being tested.Current prevention treatments include pills originally developed for epilepsy and other conditions and the wrinkle reducer Botox, but many patients abandon them because they don’t help much or ...
Source: TIME: Health - Category: Consumer Health News Authors: Tags: Uncategorized onetime Pharmaceuticals Source Type: news
More News: Brain | Epilepsy | Health | Learning | Neurology | Neurosurgery | Universities & Medical Training